独特的FLT3路径 基因表达特征 在儿科De Novo急性淋巴细胞和髓性白血病中FLT3突变:对向治疗的影响
Lizhen Zhao1, Hongbo Chen1, Fengli Lan1
1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
International journal of molecular sciences
|September 14, 2024
概括
FLT3突变对儿科急性淋巴细胞白血病 (ALL) 和急性髓性白血病 (AML) 的影响不同. 由于不同的遗传特征和路径激活,FLT3抑制剂可能对具有FLT3突变的AML患者更有益.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 激活FLT3突变与白血病发生有关.
- 最优的FLT3抑制剂治疗候选人仍在争论中.
- 了解FLT3突变对儿科白血病的影响至关重要.
研究的目的:
- 研究FLT3突变对儿科ALL和AML的影响.
- 为了比较ALL和AML之间的FLT3突变概况.
- 为了告知有针对性的FLT3抑制剂应用.
主要方法:
- 对243个ALL和62个AML病例进行了回顾性分析.
- 分类为FLT3突变体和野生类型组.
- 评估FLT3突变与临床/遗传特征之间的关联,以及预后.
主要成果:
- 在ALL中,FLT3突变与高二位积分和更高的FLT3表达相关,但并没有预后.
- 在AML中,FLT3突变与白细胞病变,NUP98重组,FLT3表达升高和预后不佳有关.
- 在AML-FLT3突变中,内部串联重复是常见的,但在ALL-FLT3突变中很少见.
结论:
- 在儿科ALL和AML之间,FLT3突变类型和影响显著不同.
- 独特的基因表达特征表明FLT3抑制剂可能更适合FLT3突变AML而不是ALL.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
13.9K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
39
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
